Lawyers for the Drug Enforcement Administration (DEA) on June 29 highlighted testimony on marijuana’s medical benefits, and its relative safety compared to other substances such as alcohol and opioids, on the opening day of a hearing on the Trump administration’s cannabis rescheduling proposal.
While the proceedings were not livestreamed to the public in line with requests from Marijuana Moment, a congressman and others, Marijuana Moment spoke to several people who were in the room to get a sense of how the testimony is going.
According to those sources, DEA lawyer James J Schwartz began by noting that the government is formally the proponent of the proposed rule to move cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III—noting that the hearing is “not about recreational use of marijuana,” and is about “regulation, not legalization.”
“All controlled substances are dangerous. However, controlled substances must be evaluated by risks they pose, balanced by medical benefits they provide.”
“The government is not putting forth any evidence to suggest marijuana is not dangerous. All controlled substances are dangerous,” he said. “However, controlled substances must be evaluated by risks they pose, balanced by medical benefits they provide.”
Dominic Chiapperino, who serves as director of the controlled substance staff with the Food and Drug Administration’s Center for Drug Evaluation and Research and is one of the DEA’s two witnesses, provided testimony about how federal health officials formed their recommendation in support of rescheduling cannabis.
They used a new two-part test that reform opponents have argued improperly departs from an earlier analysis—though the DEA lawyer said the hearing is not about that dispute—and Chiapperino said the new test is now considered “every time” a new analysis on a drug is undertaken.
The FDA official said the agency compared marijuana to alcohol, opioids and other substances when conducting its scheduling analysis, finding that day-to-day harms for marijuana were generally lower than all or most of those comparators.
Cannabis is tied to fewer overdose deaths than comparator substances, Chiapperino said, adding that when marijuana is mentioned in case reports involving deaths, the fatalities are usually attributed to secondary events like accidents or self-imposed harm. Marijuana’s potential for overdose deaths is “much lower” than other Schedule I drugs as well as Schedule II opioids, the FDA official said.
With respect to withdrawal for regular users, Chiapperino testified that cannabis has similar symptoms to those for tobacco, including irritability—but that alcohol has a “more several withdrawal syndrome” that can include seizure and death.
The DEA is in the “super-awkward position of arguing the opposite of what it’s been arguing for the last 50 years,” said the president of the prohibitionist organization Smart Approaches to Marijuana.
Also on June 29, lawyers for some of the anti-rescheduling parties had an opportunity to cross-examine Chiapperino.
Kevin Sabet, president and CEO of the prohibitionist organization Smart Approaches to Marijuana, which was also invited to participate in the hearing, said in a video posted to social media that seeing the government argue on behalf of cannabis’s medical uses and relatively low harms is “surreal”—claiming that “they’re just lying through their teeth.”
The DEA is in the “super-awkward position of arguing the opposite of what it’s been arguing for the last 50 years, the opposite of what the science says, the opposite of where the evidence is,” he said, “which, of course, is that marijuana is more harmful, not less harmful than we thought it was—the government’s trying to argue the opposite.”
On June 30, other opponents of rescheduling will get a chance to cross-examine the FDA official—and the government’s second witness, Corey Burchman, a medical doctor from New Hampshire, will begin his testimony. The DEA previewed in a June 26 filing that he will provide testimony about how “medical marijuana provides a medical benefit to pain patients.”
On June 29, a DEA lawyer said during his opening remarks at the hearing that Burchman would “describe real-world impacts of treatment of pain with marijuana instead of opioids,” based on his experience with both, and will discuss how he has “personally transitioned patients from opioids to marijuana for their pain.”
The witness will also provide testimony on the differences between cannabis and opioids when it comes to withdrawal and overdose potential, he said.
The hearing is set to conclude no later than July 15.
Ahead of the hearing’s start, marijuana reform activists held a press conference outside DEA headquarters to highlight how they feel the have been “shut out” of the process—criticizing the fact that no supporters of reform were invited to participate and that the proceedings are not being livestreamed, despite officials’ vows of “transparency.”
DEA Administrator Terrance Cole invited only organizations and people who oppose marijuana reform to join the hearing as designated participants—telling supporters that they do not meet the definition of an “interested person” to participate because they are not “adversely affected or aggrieved by any rule or proposed rule issuable.”
On June 25, Marijuana Moment sent requests to DEA Chief Administrative Law Judge Derek Julius and to Cole, the DEA administrator, requesting they reverse a decision to prohibit the public from tuning into the cannabis hearing via livestream. A congressman and other journalists later joined in that request.
Rescheduling opponents who are participating in the hearing filed statements that week previewing the anti-marijuana arguments they intend to make during the proceedings.
The hearing is set to conclude no later than July 15.
Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by FDA from Schedule I of the CSA to Schedule III.
Under a separate order the acting attorney general signed, the upcoming hearing will consider more comprehensively moving marijuana to Schedule III.
A prior hearing process on the marijuana rescheduling process that was initiated by the Biden administration stalled in 2025 amid litigation over alleged improper communications and witness selection.
The rescheduling of state-licensed medical cannabis is already having broad impacts.
The current marijuana rescheduling process is being challenged with several lawsuits that have been consolidated by a federal appeals court. Those pieces of litigation against the cannabis reform have been filed by state attorneys general, marijuana legalization opponents and a cannabis-focused biopharmaceutical corporation.
Meanwhile, the already-enacted rescheduling of state-licensed medical cannabis is already having broad impacts.
The Congressional Research Service published a report on the current cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says.
The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has posted a draft update to a gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The revised section in question notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis.
The United States Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances.
Even the DEA, which has long opposed cannabis legalization and was accused of stalling the rescheduling process initiative by the Biden administration, has launched a registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform.
The Department of Transportation, on the other hand, issued guidance saying that use of state-legal medical cannabis is still no excuse for a positive drug test by truck drivers, pilots and other safety-sensitive workers.
A congressional committee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling, though bipartisan lawmakers told Marijuana Moment they don’t believe that provision will be enacted into law.
Photograph (cropped) by Matthew Brodeur on Unsplash
This story was originally published by Marijuana Moment, which tracks the politics and policy of cannabis and drugs. Follow Marijuana Moment on X and Facebook, and sign up for its newsletter.
